关键信息
-
基因名
MAGEB4
- 应用
-
别名
cancer/testis antigen family 3. member 6; CT3.6; MAGB4_HUMAN; MAGE B4 antigen ; MAGE-B4 antigen; MAGEB4; melanoma antigen family B. 4; Melanoma associated antigen B4; Melanoma-associated antigen B4; MGC33144
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O15481
-
表达区间
1-346aa
-
氨基酸序列
MPRGQKSKLR AREKRQRTRG QTQDLKVGQP TAAEKEESPS SSSSVLRDTA SSSLAFGIPQ EPQREPPTTS AAAAMSCTGS DKGDESQDEE NASSSQASTS TERSLKDSLT RKTKMLVQFL LYKYKMKEPT TKAEMLKIIS KKYKEHFPEI FRKVSQRTEL VFGLALKEVN PTTHSYILVS MLGPNDGNQS SAWTLPRNGL LMPLLSVIFL NGNCAREEEI WEFLNMLGIY DGKRHLIFGE PRKLITQDLV QEKYLEYQQV PNSDPPRYQF LWGPRAHAET SKMKVLEFLA KVNDTTPNNF PLLYEEALRD EEERAGARPR VAARRGTTAM TSAYSRATSS SSSQPM
-
分子量
38.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MAGEB4 (Melanoma Antigen Gene B4) is a member of the MAGE family of genes, which are known for their role in tumorigenesis and immune response modulation. This gene is predominantly expressed in testicular germ cells and various malignant tumors, making it a candidate for cancer immunotherapy targeting. Research on MAGEB4 has gained momentum due to its potential as a tumor-associated antigen, which can elicit specific immune responses in cancer patients. The recombinant protein derived from MAGEB4 is being studied for its ability to stimulate T-cell responses, offering a promising avenue for vaccine development and personalized cancer treatment. Moreover, understanding the structure and function of MAGEB4 can facilitate the design of targeted therapies that can selectively attack cancer cells while sparing normal tissues. As the field of cancer immunotherapy continues to evolve, MAGEB4 presents a significant interest due to its implications in improving patient outcomes and advancing the understanding of tumor immune evasion mechanisms.
